Tessa Malaika van Ginhoven

Tessa Malaika van Ginhoven

Auto-generated profile, based on publicly available information

Tessa Malaika van Ginhoven

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center , 3015 GD Rotterdam

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Surgery
Verified
Journal Article
Open access
PJPascal K.C. Jonker
Pascal K.C. Jonker
WPWillemijn Y. van der Plas
Willemijn Y. van der Plas
PSPieter Steinkamp
Pieter Steinkamp
RPRalph Poelstra
Ralph Poelstra
MEMarloes Emous
Marloes Emous
SKShirley Ketting
Shirley Ketting
A direct comparison of severe acute respiratory syndrome coronavirus 2 positive patients with a severe acute respiratory syndrome coronavirus 2 negative control group undergoing an operative intervention during the current pandemic is lacking, and a reliable estimate of the assumed difference in morbidity and mortality between both patient categories remains unknown. We included all consecutive patients with a confirmed pre- or postoperative severe acute respiratory syndrome coronavirus 2 positive status (operated in 27 hospitals) and negative control patients (operated in 4 hospitals) undergoing emergency or elective operations. A propensity score-matched comparison of clinical outcomes was performed between severe acute respiratory syndrome coronavirus 2 positive and negative tested patients (control group). Primary outcome was overall 30-day mortality rate between both groups. Main secondary outcomes were overall, pulmonary, and thromboembolic complications. In total, 161 severe acute respiratory syndrome coronavirus 2 positive and 342 control severe acute respiratory syndrome coronavirus 2 negative patients were included in this study. The 30-day overall postoperative mortality rate was greater in the severe acute respiratory syndrome coronavirus 2 positive cohort compared with the negative control group (16% vs 4% respectively; P = .007). After propensity score matching, the severe acute respiratory syndrome coronavirus 2 positive group consisted of 123 patients (median 70 years of age [interquartile range 59–77] and 55% male) were compared with 196 patients in the matched control group (median 69 years (interquartile range 58–75] and 53% male). The 30-day mortality rate and risk were greater in the severe acute respiratory syndrome coronavirus 2 positive group compared with the matched control group (12% vs 4%; P = .009 and odds ratio 3.4 [95% confidence interval 1.5–8.5]; P = .005, respectively). Overall, pulmonary and thromboembolic complications occurred more often in severe acute respiratory syndrome coronavirus 2 positive patients (P < .01). Patients diagnosed with perioperative severe acute respiratory syndrome coronavirus 2 have an increased risk of 30-day mortality, pulmonary complications, and thromboembolic events. These findings serve as an evidence-based argument to postpone elective surgery and selected emergency cases.

10 February 2022 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SDSam P. J. van Dijk
Sam P. J. van Dijk
HCHannelore I. Coerts
Hannelore I. Coerts
SGSabrina T. G. Gunput
Sabrina T. G. Gunput
EVEvert F. S. van Velsen
Evert F. S. van Velsen
MMMarco Medici
Marco Medici
TGTessa M. van Ginhoven
Tessa M. van Ginhoven
Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid malignant neoplasm, accounting for approximately 85% of thyroid cancers.1 Papillary thyroid carcinomas measuring 10 mm or less were first defined by the World Health Organization as papillary thyroid microcarcinomas (mPTCs).2 Papillary thyroid microcarcinomas account for an increasing proportion of thyroid cancers; in some countries, almost half of all PTCs are classified as an mPTC.3-5 Patients with a diagnosis of mPTC have a disease-specific survival of more than 99% after 10 years of follow-up.6,7

7 October 2021 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
ILIvona Lončar
Ivona Lončar
MNMilou E. Noltes
Milou E. Noltes
CDChris Dickhoff
Chris Dickhoff
AEAnton F. Engelsman
Anton F. Engelsman
ASAbbey Schepers
Abbey Schepers
TGTessa M. van Ginhoven
Tessa M. van Ginhoven
The parathyroid glands are usually 4 delicate structures 3 to 4 mm in size and located close to the thyroid gland. Their function is to maintain calcium (Ca) homeostasis by producing the parathyroid hormone (PTH). Unfortunately, these organs are at risk of damage during thyroid surgery, potentially resulting in postoperative hypoparathyroidism (hypoPT). HypoPT is one of the most common complications after total or completion thyroidectomy and is in most patients caused by accidental damage or resection of parathyroid glands or impaired blood supply.1,2 Immediate clinical signs of hypoPT due to hypocalcemia are perioral numbness, muscle cramps, and paresthesia, as well as severe seizures and cardiac arrhythmias in rare instances. In the case of persistent hypoPT, patients are at risk for kidney complications, impaired quality of life, and increased mortality rates.3-5 Transient hypoPT (parathyroid function restores within the first year after surgery) occurs in up to 19% to 38% of patients after total or completion thyroidectomy.6 Patients with hypoPT beyond this period are usually classified as having persistent hypoPT.7-9 Data from high-volume single centers show frequencies of persistent hypoPT less than 5%. A single-center study from Sweden and a Korean case series published a 1.9% and 1.5% incidence rate, respectively.8,10 Another single-center study from Austria and a French multicenter study showed even lower incidences of 1.2% and 1.0%, respectively.11,12 However, recent registries and nationwide multicentric studies reported much higher incidence rates. A Swedish population-based study reported a persisting hypoPT rate of 14.5%, and a Spanish multicenter nationwide study reported an even higher incidence rate of 16.7%.7,13 The British Association of Endocrine and Thyroid Surgeons (BAETS) reported a 7.3% rate in their fifth national audit, and a survey from the Thyroid Cancer Alliance yielded a 13.8% rate.9,14 This variety in reported incidence rates might be partially explained by the absence of an international standardized definition for persistent hypoPT,15 differences in case mix, and underreporting of this complication. Despite the fact that there is substantial literature on the incidence of hypoparathyroidism, uniform diagnosis and treatment guidelines are still lacking. We hypothesized that the incidence of hypoparathyroidism in the literature is underreported because there are no diagnostic guidelines, and national registries and multicenter studies demonstrate substantially different outcomes compared with single-center studies.

8 July 2021 in Thyroid®
Verified
Journal Article
Closed access
EVEvert F.S. van Velsen
Evert F.S. van Velsen
WVW. Edward Visser
W. Edward Visser
MSMerel Tessa Stegenga
Merel Tessa Stegenga
UMUwe Maeder
Uwe Maeder
Christoph ReinersChristoph Reiners
Christoph Reiners
RPRobin P. Peeters
Robin P. Peeters
Background: Differentiated thyroid cancer (DTC) is the only cancer entity for which the UICC/AJCC (Union for International Cancer Control and American Joint Committee on Cancer) TNM (tumor–node–metastasis) staging system involves an age cutoff as a prognostic criterion. However, the optimal age cutoff has not yet been determined in detail. The aim of our study was therefore to investigate the optimal age cutoff for the TNM staging system to predict disease-specific survival (DSS) with a focus on differences between patients with papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Methods: We retrospectively studied two large well-described cohorts of adult DTC patients from a Dutch and a German university hospital. DSS was analyzed for DTC overall, and for PTC and FTC separately, using several age cutoffs (per 5-year increment between 20 and 85 years and subsequently 1-year increments between 35 and 55 years), employing the histopathological criteria from the TNM staging system, eighth edition. Results: We included 3074 DTC patients (77% PTC and 23% FTC; mean age at diagnosis was 49 years). Median follow-up was seven years. For DTC and for PTC and FTC separately, the majority of the age cutoffs had a better statistical model performance than a model with no age cutoff. For DTC overall and for PTC, an age cutoff of 50 years had the best statistical model performance, while it was 40 years for FTC. Conclusions: In this large European population of DTC patients, when employing the histopathological criteria of the TNM system (eighth edition), the optimal age cutoff to predict DSS is 50 years rather than the 55 years currently in use. With the optimal age cutoff being 50 years for PTC and 40 years for FTC, there was a substantial difference in age cutoff for the respective histological entities. Therefore, implementation of different age cutoffs for PTC and FTC could improve the predictive value of the TNM staging system.

30 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CVCharlotte Viëtor
Charlotte Viëtor
SCSara G. Creemers
Sara G. Creemers
FKFolkert Kemenade
Folkert Kemenade
TGTessa M. van Ginhoven
Tessa M. van Ginhoven
LHLeo J. Hofland
Leo J. Hofland
RFRichard A. Feelders
Richard A. Feelders
Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Adrenal incidentalomas are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance considering the large differences in clinical behavior requiring different strategies. Diagnosis of ACC starts with a thorough physical examination, biochemical evaluation, and imaging. Computed tomography is the first-level imaging modality in adrenal tumors, with tumor size and Hounsfield units being important features for determining malignancy. New developments include the use of urine metabolomics, also enabling discrimination of ACC from adenomas preoperatively. Postoperatively, the Weiss score is used for diagnosis of ACC, consisting of nine histopathological criteria. Due to known limitations as interobserver variability and lack of accuracy in borderline cases, much effort has been put into new tools to diagnose ACC. Novel developments vary from immunohistochemical markers and pathological scores, to markers at the level of DNA, methylome, chromosome, or microRNA. Molecular studies have provided insights into the most promising and most frequent alterations in ACC. The use of liquid biopsies for diagnosis of ACC is studied, although in a small number of patients, requiring further investigation. In this review, current diagnostic modalities and challenges in ACC will be addressed.

3 August 2021 in Thyroid®
Verified
Journal Article
Closed access
ILIvona Lončar
Ivona Lončar
SDSam P.J. van Dijk
Sam P.J. van Dijk
MMMadelon Metman
Madelon Metman
JLJia Feng Lin
Jia Feng Lin
SKSchelto Kruijff
Schelto Kruijff
TGTessa Malaika van Ginhoven
Tessa Malaika van Ginhoven
Background: The worldwide incidence of papillary thyroid carcinoma (PTC) has increased. Efforts to reduce overtreatment follow two approaches: limiting diagnostic workup of low-risk thyroid nodules and pursuing active surveillance (AS) after diagnosis of microscopic PTC (mPTC). However, most studies on AS have been performed in countries with a relatively high proportion of overdiagnosis and thus incidental mPTC. The role of AS in a population with a restrictive diagnostic workup protocol for imaging and fine-needle aspiration remains unknown. Therefore, the aim of this study was to describe the proportion and characteristics of patients with mPTC in the Netherlands and to describe the potential candidates for AS in a situation with restrictive diagnostic protocols since 2007. Methods: All operated patients with an mPTC in the Netherlands between 2005 and 2015 were identified from the Netherlands Cancer Registry database. Three groups were defined: (Group 1) mPTC with preoperative distant or lymph node metastases, (Group 2) mPTC in pathology report after thyroid surgery for another indication, and (Group 3) patients with a preoperative high suspicious thyroid nodule or proven mPTC (Bethesda 5 or 6). Only patients in Group 3 were considered potential candidates for AS. Results: A total of 1018 mPTC patients were identified. Group 1 consisted of 152 patients with preoperatively discovered metastases. Group 2 consisted of 667 patients, of whom 16 (2.4%) had lymph node metastases. There were 199 patients in Group 3, of whom 27 (13.6%) had lymph node metastases. After initial treatment in Group 3, 3.5% (7/199) of the patients had recurrence. Conclusions: Restrictive diagnostic workup strategies of patients with small thyroid nodules lead to limited patients eligible for AS and a higher incidence of lymph node metastases. We believe that there is limited additive value for AS in countries with restrictive diagnostic workup guidelines such as in the Netherlands. However, if an mPTC is encountered, AS can be offered on an individual basis.